NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of BioMarin Pharmaceutical Inc. ( BMRN) from February 28, 2020 through August 18, 2020. If you wish to serve as lead plaintiff, you must move the Court before the NOVEMBER 24, 2020 DEADLINE.
To join the class action, go to http://zhanginvestorlaw.com/join-action-form/?slug=biomarin-pharmaceutical-inc&id=2428 or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email [email protected] for information on the class action.
如果您想加入这个集体诉讼案，请在这里提交您的信息。http://zhanginvestorlaw.com/join-action-form/?slug=biomarin-pharmaceutical-inc&id=2428
If you wish to serve as lead plaintiff, you must move the Court before the NOVEMBER 24, 2020 DEADLINE. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose, among other things: differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec’s durability of effect; as a result, it was foreseeable that the U.S. Food and Drug Administration would not approve the Biologics License Application for valoctocogene roxaparvovec without additional data; and as a result, the Company’s public statements were materially false and misleading at all relevant times.
Lead plaintiff status is not required to seek compensation. You may retain counsel of your choice. You may remain an absent class member and take no action at this time.
Zhang Investor Law represents investors worldwide. Attorney Advertising. Prior results do not guarantee similar outcomes.
Zhang Investor Law P.C.
99 Wall Street, Suite 232
New York, New York 10005
[email protected]
tel: (800) 991-3756
